| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
50.94
|
|
2
|
Predictive value of BMD for hip and other fractures.
|
J Bone Miner Res
|
2005
|
6.46
|
|
3
|
Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.
|
J Bone Miner Res
|
2013
|
5.93
|
|
4
|
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
|
J Clin Oncol
|
2002
|
3.01
|
|
5
|
The cost-effectiveness of alendronate in the management of osteoporosis.
|
Bone
|
2007
|
2.75
|
|
6
|
Does osteoporosis therapy invalidate FRAX for fracture prediction?
|
J Bone Miner Res
|
2012
|
2.22
|
|
7
|
Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women.
|
J Bone Miner Res
|
2008
|
2.20
|
|
8
|
Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).
|
Arch Osteoporos
|
2011
|
2.14
|
|
9
|
Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration.
|
J Bone Miner Res
|
2010
|
1.90
|
|
10
|
Trabecular bone score: a noninvasive analytical method based upon the DXA image.
|
J Bone Miner Res
|
2014
|
1.86
|
|
11
|
FRAX underestimates fracture risk in patients with diabetes.
|
J Bone Miner Res
|
2012
|
1.82
|
|
12
|
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.
|
J Bone Miner Res
|
2012
|
1.77
|
|
13
|
Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis.
|
J Bone Miner Res
|
2008
|
1.69
|
|
14
|
The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach.
|
Osteoporos Int
|
2004
|
1.60
|
|
15
|
A meta-analysis of the association of fracture risk and body mass index in women.
|
J Bone Miner Res
|
2014
|
1.56
|
|
16
|
Type 2 diabetes and bone.
|
J Bone Miner Res
|
2012
|
1.53
|
|
17
|
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.
|
Calcif Tissue Int
|
2011
|
1.50
|
|
18
|
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
|
Bone
|
2008
|
1.48
|
|
19
|
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
|
J Bone Miner Res
|
2007
|
1.45
|
|
20
|
Association between vertebral fracture and increased mortality in osteoporotic patients.
|
J Bone Miner Res
|
2003
|
1.39
|
|
21
|
Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS).
|
Bone
|
2003
|
1.37
|
|
22
|
Risk factors for incident vertebral fractures in men and women: the Rotterdam Study.
|
J Bone Miner Res
|
2004
|
1.27
|
|
23
|
Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study.
|
Osteoporos Int
|
2005
|
1.23
|
|
24
|
Cortical porosity identifies women with osteopenia at increased risk for forearm fractures.
|
J Bone Miner Res
|
2014
|
1.21
|
|
25
|
Quality of life in sarcopenia and frailty.
|
Calcif Tissue Int
|
2013
|
1.17
|
|
26
|
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.
|
J Bone Miner Res
|
2004
|
1.16
|
|
27
|
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
|
J Bone Miner Res
|
2004
|
1.14
|
|
28
|
Milk intake and risk of hip fracture in men and women: a meta-analysis of prospective cohort studies.
|
J Bone Miner Res
|
2011
|
1.11
|
|
29
|
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.
|
Clin Chem Lab Med
|
2011
|
1.10
|
|
30
|
Optimization of BMD measurements to identify high risk groups for treatment--a test analysis.
|
J Bone Miner Res
|
2004
|
1.05
|
|
31
|
Adjusting fracture probability by trabecular bone score.
|
Calcif Tissue Int
|
2015
|
1.04
|
|
32
|
Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men.
|
J Bone Miner Res
|
2004
|
1.02
|
|
33
|
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
|
Bone
|
2004
|
1.01
|
|
34
|
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.
|
J Clin Densitom
|
2011
|
1.00
|
|
35
|
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
|
Semin Arthritis Rheum
|
2013
|
0.95
|
|
36
|
Incidence of hip fracture in Romania and the development of a Romanian FRAX model.
|
Calcif Tissue Int
|
2013
|
0.93
|
|
37
|
Fracture risk assessment.
|
Clin Biochem
|
2012
|
0.93
|
|
38
|
Inflammatory bowel disease and the risk of fracture after controlling for FRAX.
|
J Bone Miner Res
|
2013
|
0.93
|
|
39
|
High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden.
|
J Bone Miner Res
|
2012
|
0.92
|
|
40
|
A meta-analysis of reference markers of bone turnover for prediction of fracture.
|
Calcif Tissue Int
|
2014
|
0.91
|
|
41
|
Potential impact of osteoporosis treatment on hip fracture trends.
|
J Bone Miner Res
|
2005
|
0.91
|
|
42
|
The effect of latitude on the risk and seasonal variation in hip fracture in Sweden.
|
J Bone Miner Res
|
2014
|
0.90
|
|
43
|
FRAX updates 2012.
|
Curr Opin Rheumatol
|
2012
|
0.90
|
|
44
|
Smoking predicts incident fractures in elderly men: Mr OS Sweden.
|
J Bone Miner Res
|
2010
|
0.88
|
|
45
|
From relative risk to absolute fracture risk calculation: the FRAX algorithm.
|
Curr Osteoporos Rep
|
2009
|
0.88
|
|
46
|
Assessing the impact of osteoporosis on the burden of hip fractures.
|
Calcif Tissue Int
|
2012
|
0.88
|
|
47
|
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
|
Bone
|
2007
|
0.87
|
|
48
|
Epidemiology of fracture in the Russian Federation and the development of a FRAX model.
|
Arch Osteoporos
|
2012
|
0.87
|
|
49
|
A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.
|
Pharmacoeconomics
|
2015
|
0.87
|
|
50
|
Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model.
|
Arch Osteoporos
|
2011
|
0.86
|
|
51
|
How to define responders in osteoarthritis.
|
Curr Med Res Opin
|
2013
|
0.86
|
|
52
|
Health technology assessment in osteoporosis.
|
Calcif Tissue Int
|
2013
|
0.85
|
|
53
|
Hip axis length is a FRAX- and bone density-independent risk factor for hip fracture in women.
|
J Clin Endocrinol Metab
|
2015
|
0.84
|
|
54
|
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
|
Pharmacoeconomics
|
2004
|
0.84
|
|
55
|
Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
|
J Clin Densitom
|
2011
|
0.84
|
|
56
|
European guidance for the diagnosis and management of osteoporosis in postmenopausal women--what is the current message for clinical practice?
|
Pol Arch Med Wewn
|
2008
|
0.84
|
|
57
|
Health economics of osteoporosis.
|
Best Pract Res Clin Endocrinol Metab
|
2008
|
0.83
|
|
58
|
The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
|
Endocrine
|
2015
|
0.82
|
|
59
|
Can change in FRAX score be used to "treat to target"? A population‐based cohort study.
|
J Bone Miner Res
|
2014
|
0.82
|
|
60
|
Estimated lean mass and fat mass differentially affect femoral bone density and strength index but are not FRAX independent risk factors for fracture.
|
J Bone Miner Res
|
2014
|
0.82
|
|
61
|
Critical issues in translational and clinical research for the study of new technologies to enhance bone repair.
|
J Bone Joint Surg Am
|
2008
|
0.82
|
|
62
|
The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks.
|
Value Health
|
2007
|
0.82
|
|
63
|
FRAX updates 2016.
|
Curr Opin Rheumatol
|
2016
|
0.82
|
|
64
|
Cost-effectiveness of hormone therapy in the United States.
|
J Womens Health (Larchmt)
|
2009
|
0.81
|
|
65
|
Selection of women aged 50-64 yr for bone density measurement.
|
J Clin Densitom
|
2013
|
0.80
|
|
66
|
Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model.
|
Calcif Tissue Int
|
2012
|
0.79
|
|
67
|
Potential Extensions of the US FRAX Algorithm.
|
J Osteoporos
|
2012
|
0.78
|
|
68
|
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty.
|
Drugs Aging
|
2015
|
0.78
|
|
69
|
FRAX-based intervention and assessment thresholds for osteoporosis in Romania.
|
Arch Osteoporos
|
2013
|
0.78
|
|
70
|
The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland.
|
Pol Arch Med Wewn
|
2011
|
0.77
|
|
71
|
The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study.
|
Arch Osteoporos
|
2012
|
0.76
|
|
72
|
FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
|
J Clin Densitom
|
2011
|
0.76
|
|
73
|
Standardising biochemical assessment of bone turnover in osteoporosis.
|
Clin Biochem
|
2011
|
0.75
|
|
74
|
[FRAX--model for 10-year fracture risk assessment. Support in the treatment of osteoporosis, according to preliminary Swedish guidelines].
|
Lakartidningen
|
2011
|
0.75
|
|
75
|
Development and application of FRAX in the management of osteoporosis in Ireland.
|
Arch Osteoporos
|
2013
|
0.75
|
|
76
|
Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007.
|
Osteoporos Int
|
2007
|
0.75
|
|
77
|
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK.
|
Menopause Int
|
2009
|
0.75
|
|
78
|
Recommendations for bone marker standards in osteoporosis: what, why and where to now?
|
Ann Clin Biochem
|
2011
|
0.75
|